Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Stock Trading Plan

6 Oct 2016 18:01

RNS Number : 9410L
GW Pharmaceuticals PLC
06 October 2016
 

Director Stock Trading Plan

London, UK; 6 October 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: "GWP," "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, has today been notified that Mr Justin Gover, its Chief Executive Officer, has established a personal stock trading plan in accordance both with the guidelines established by Rule 10b5-1 under the U.S. Securities Exchange Act of 1934, as amended, and the EU Market Abuse Regulation, as well as the Company's policies with respect to insider sales.

Rule 10b5-1 plans permit directors, officers and other company insiders to adopt, at times when they are not in possession of material, non-public information, written plans for trading securities in a non-discretionary, pre-scheduled manner in the future. These pre-planned trades can then be executed at a later date, as spelled out in the plan, without further action by the director, officer or other company insider and without regard to any subsequent non-public information the individual might have received.

Mr Gover's plan provides for the exercise and sale of options over up to 362,144 Ordinary 0.1p Shares (equivalent to 30,178 American Depository Shares), between 9 December 2016 and 1 April 2017 in order to avoid otherwise adverse personal taxation implications of non-exercise of these options.

Following exercise of these options, Mr Gover will continue to hold 1,067,972 options over Ordinary Shares (equivalent to 88,997 ADSs) and will continue to be the beneficial owner of an additional 2,513,759 Ordinary Shares (equivalent to 209,479 ADSs).

The transactions under the plan will be disclosed publicly through Form 144 and Form 4 filings as required by the U.S. Securities and Exchange Commission, and by announcement through a Regulatory Information Service, as required by the EU Market Abuse Regulation.

For further information, please contact:

 

GW Pharmaceuticals PLC +44 (0)1980 557 000

Adam George, Company Secretary

 

Peel Hunt LLP (Nominated Adviser)

James Steel/Oliver Jackson +44 (0) 20 7418 8900

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHQQLFBQBFEFBV
Date   Source Headline
10th May 20134:24 pmRNSHolding(s) in Company
9th May 20133:40 pmRNSTotal Voting Rights
8th May 20138:00 amRNSClosing of Initial Public Offering on Nasdaq
7th May 20137:00 amRNSSativex Commercialization Approval in Italy
1st May 20135:47 pmRNSPricing of U.S. Initial Public Offering
22nd Apr 20137:00 amRNSUS Patent Allowance for SATIVEX Formulation Spray
18th Apr 20132:23 pmRNSAmendment to Registration Statement for NASDAQ
12th Apr 201310:31 amRNSResults of General Meeting
10th Apr 20137:00 amRNSSativex moved to Schedule 4 of UK Drugs Act
3rd Apr 20137:00 amRNSNew US Patent Allowance for Delivery of SATIVEX
22nd Mar 20132:35 pmRNSPosting of Shareholder Circular
19th Mar 20132:46 pmRNSAppoints Stephen Schultz VP of Investor Relations
19th Mar 20131:10 pmRNSUpdate on Sativex in Germany
19th Mar 20131:01 pmRNSFiling for listing on NASDAQ
19th Feb 20133:16 pmRNSDirectorate Change
19th Feb 20139:30 amRNSBlocklisting Interim Review
4th Dec 201210:04 amRNSDirector/PDMR Shareholding
30th Nov 20122:54 pmRNSDirector/PDMR Shareholding
30th Nov 20122:50 pmRNSDirector/PDMR Shareholding
28th Nov 20127:00 amRNSPreliminary Results
28th Nov 20127:00 amRNSPhIIa Study Identifies New Anti-Diabetic Treatment
22nd Nov 201211:31 amRNSNotice of Results
12th Nov 20127:00 amRNSGW to Present at Lazard Healthcare Conference
12th Oct 20127:00 amRNSPositive German Sativex Data Presented at ECTRIMS
1st Oct 20127:00 amRNSAppointment of Chief Operating Officer
13th Sep 20127:00 amRNSPublication of New Epilepsy Data
20th Aug 201212:14 pmRNSDirector/PDMR Shareholding
17th Aug 20124:04 pmRNSBlocklisting Interim Review
22nd Jun 20127:00 amRNSGerman GBA establishes positive benefit of Sativex
13th Jun 201210:19 amRNSDirector/PDMR Shareholding
6th Jun 20124:03 pmRNSDirector/PDMR Shareholding
23rd May 20123:56 pmRNSDirector/PDMR Shareholding
22nd May 20127:00 amRNSThird Cancer Pain Trial Commences
22nd May 20127:00 amRNSInterim Results
8th May 20127:00 amRNSSuccessful completion of MRP for Sativex
26th Apr 201211:00 amRNSNotice of Results
23rd Apr 20127:00 amRNSSativex phase IIb pain trial results publication
16th Apr 20127:00 amRNSAlmirall Milestone
5th Apr 20127:00 amRNSBoard Changes
2nd Apr 20122:31 pmRNSDirector/PDMR Shareholding
30th Mar 20121:57 pmRNSDirector/PDMR Shareholding
15th Mar 20127:00 amRNSGW and Almirall Strengthen Strategic Collaboration
8th Mar 20127:00 amRNSAppointment of Professor Vincenzo Di Marzo
17th Feb 20127:00 amRNSBlocklisting Interim Review
7th Feb 20127:00 amRNSSATIVEX® Regulatory Approval Received in Austria
25th Jan 20121:46 pmRNSResult of AGM
11th Jan 201211:43 amRNSHolding(s) in Company
11th Jan 201211:42 amRNSHolding(s) in Company
28th Dec 201110:39 amRNSDirector/PDMR Shareholding
22nd Dec 20117:00 amRNSSativex Approval in Sweden

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.